{"id":18968,"date":"2022-01-18T15:32:36","date_gmt":"2022-01-18T14:32:36","guid":{"rendered":"https:\/\/www.idisantiago.es\/grupo-de-investigacion\/e045-cardiologia-traslacional\/"},"modified":"2026-01-16T09:40:15","modified_gmt":"2026-01-16T08:40:15","slug":"e045-cardiologia-traslacional","status":"publish","type":"project","link":"https:\/\/www.idisantiago.es\/en\/grupo-de-investigacion\/e045-cardiologia-traslacional\/","title":{"rendered":"E045 – Translational Cardiology"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||||false|false” da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” custom_padding=”0px||||false|false” locked=”on” collapsed=”on” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”]\u00c1REA: CARDIOVASCULAR<\/a>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”2_3,1_3″ _builder_version=”4.16″ _module_preset=”default” width=”100%” global_colors_info=”{}”][et_pb_column type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image title_text=”Corporate portrait of office workers and employees” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_toggle title=”Objectives and lines of research” admin_label=”Objetivos y l\u00edneas de investigaci\u00f3n” _builder_version=”4.19.4″ _module_preset=”default” body_font=”|300|||||||” global_colors_info=”{}”]<\/p>\n

Objectives<\/h3>\n

The research group is led by a basic principal investigator, Sonia Eiras Penas (specialist in cardiac fat), and a principal clinical investigator, Mois\u00e9s Rodr\u00edguez Ma\u00f1ero (specialist in arrhythmias). Both work together to provide solutions to medical needs in the diagnosis, treatment and monitoring of patients with cardiovascular disease, focusing mainly on cardiac fat and arrhythmias. To achieve the objective, the group focuses on the following studies:
a) Physiopathological mechanisms of cardiovascular disease associated with cardiac fat.
b) Regulatory factors and treatments of the genesis of cardiac fat.
c) New biochemical and cellular indicators, associated with cardiac fat, for the diagnosis and prognosis of cardiovascular disease.
d) Preclinical models that improve the understanding of the cardiac fat-immune and cardiovascular system network.
e) New procedures in the treatment of atrial fibrillation.
f) New risk indicators of atrial fibrillation and its perpetuation.<\/p>\n

Lines of research<\/h3>\n

1. Epicardial fat and cardiovascular pathology
Since 2005, our group has focused on the study of a) the pathophysiological mechanisms in epicardial fat involved in cardiovascular disease (atrial fibrillation, ischemic heart disease or heart failure) and their risk factors b) search for non-invasive markers and easy access of pathogenic epicardial fat, c) paracrine and endocrine activity that allows the identification of systemic markers of cardiovascular pathology and c) its regulation by drugs. For this we have established technologies and preclinical models that are detailed below:
a.1. proteomic, transcriptomic and functional studies (interactome-signaling pathways-therapeutic targets or pathology markers).
a.2. “ex vivo” and “in vitro” models of tissue explants and epicardial fat cells, respectively, as well as cell co-culture systems. Established preclinical models allow us to study the genesis of epicardial fat and its regulation by existing or newly prescribed cardiovascular disease treatments.
2. Interaction epicardial fat, innate immune system and cardiovascular pathology
The inflammatory process triggered by epicardial fat favors the progression of cardiovascular disease. Thus, our group tries to study the mechanisms involved in the interaction between epicardial fat and phagocytic cells and their possible pharmacological regulation.
3. Systemic markers derived from the epicardium in cardiovascular pathology (new diagnostic kits)
Through the application of new technologies and preclinical models, we will try to study the secretory activity of the epicardium and epicardial fat to identify biochemical and cellular markers at the systemic level of the progression of cardiovascular disease, focusing mainly on atrial fibrillation and heart failure. The results of this study will allow the design of new diagnostic kits for the needs of patients.<\/p>\n

[\/et_pb_toggle][et_pb_toggle title=”Research team” admin_label=”Equipo investigador” _builder_version=”4.21.0″ _module_preset=”default” body_font=”|300|||||||” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n\n\n\n
Leader<\/strong>
Eiras Penas, Sonia<\/p>\n

 <\/p>\n

Coleader\u00a0<\/strong>
Rodr\u00edguez Ma\u00f1ero, Mois\u00e9s<\/p>\n

 <\/p>\n

Members
<\/strong>Basdas, Rumeysa
Fu, Xiaoran
Mart\u00ednez Cereijo, Jos\u00e9 Manuel
N\u00fa\u00f1ez Caama\u00f1o, Jos\u00e9 Ram\u00f3n
Sahal, Saja
Tilves Bellas, Carlos
Trincado Ave, Mauro
Vi\u00f1uela Rold\u00e1n, Juan Evaristo<\/p>\n

External Collaborator Staff<\/strong>
Couselo Seijas, Marinela
L\u00f3pez Canoa, Jos\u00e9 Nicol\u00e1s
S\u00e1nchez L\u00f3pez, David<\/p>\n<\/td>\n

\u00a0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

[\/et_pb_toggle][et_pb_toggle title=”Projects” admin_label=”Proyectos (cambiar s\u00f3 codigo IDIS)” _builder_version=”4.16″ _module_preset=”default” body_font=”|300|||||||” locked=”on” global_colors_info=”{}”]<\/p>\n\n

[\/et_pb_toggle][et_pb_toggle title=”Publications” admin_label=”Publicaciones” _builder_version=”4.19.4″ _module_preset=”default” body_font=”|300|||||||” global_colors_info=”{}”]<\/p>\n